HomeNewsNeuroscience

  • Biogen launches Aby App for Multiple Sclerosis patients

    • June 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Another Alzheimer’s drug by Lilly & AstraZeneca fails clinical trials

    • June 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Prophylactic Migraine drug Atogepant displays positive efficacy and safety results in Ph 2b/3 trials

    • June 13, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Bacteriophages might be a potential cause of Parkinson’s disease, research finds

    • June 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA approves Alembic’s generic drug for Major Depressive Disorder

    • June 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Alzheimer’s effects reversed in Mice with an Asthma drug

    • June 11, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Alder appoints new CEO to better prepare for Migraine drug launch

    • June 9, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Atrophied Brain Lesion Volume could be a new biomarker for Progressive MS, study suggests

    • June 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2 data for Ublituximab shows encouraging efficacy results in RMS patients

    • June 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Oxford BioMedica & Axovant Sciences sign a $842.5 Mn deal for Parkinson’s Drug

    • June 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more